Huntington Disease - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Huntington Disease - Pipeline Review, H1 2018’, provides an overview of the Huntington Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Huntington Disease

The report reviews pipeline therapeutics for Huntington Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Huntington Disease therapeutics and enlists all their major and minor projects

The report assesses Huntington Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Huntington Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Huntington Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Huntington Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

AFFiRiS AG

Annexon Inc

Azevan Pharmaceuticals Inc

BioCrea GmbH

BrainStorm Cell Therapeutics Inc

Celon Pharma SA

Chong Kun Dang Pharmaceutical Corp

Evotec ...

Addex Therapeutics Ltd

AFFiRiS AG

Annexon Inc

Azevan Pharmaceuticals Inc

BioCrea GmbH

BrainStorm Cell Therapeutics Inc

Celon Pharma SA

Chong Kun Dang Pharmaceutical Corp

Evotec AG

Exicure Inc

F. Hoffmann-La Roche Ltd

Genervon Biopharmaceuticals LLC

Horizon Pharma Plc

Immungenetics AG

InMed Pharmaceuticals Inc

Kadmon Corp LLC

Living Cell Technologies Ltd

Medesis Pharma SA

MindImmune Therapeutics Inc

Mitochon Pharmaceuticals Inc

Neurimmune Holding AG

Neurocrine Biosciences Inc

NeuroNascent Inc

New World Laboratories Inc

nLife Therapeutics SL

Novartis AG

Omeros Corp

Oryzon Genomics SA

Priavoid GmbH

Probiodrug AG

ProQR Therapeutics NV

PTC Therapeutics Inc

QR Pharma Inc

reMYND NV

Shire Plc

SOM Biotech SL

Spark Therapeutics Inc

Stealth BioTherapeutics Inc

Takeda Pharmaceutical Co Ltd

Teva Pharmaceutical Industries Ltd

Ultragenyx Pharmaceutical Inc

UniQure NV

Vaccinex Inc

Vertex Pharmaceuticals Inc

Vitality Biopharma Inc

Voyager Therapeutics Inc

Vybion Inc

WAVE Life Sciences Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Huntington Disease – Overview 6

Huntington Disease – Therapeutics Development 7

Huntington Disease – Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 5

Huntington Disease – Overview 6

Huntington Disease – Therapeutics Development 7

Huntington Disease – Therapeutics Assessment 20

Huntington Disease – Companies Involved in Therapeutics Development 30

Huntington Disease – Drug Profiles 51

Huntington Disease – Dormant Projects 254

Huntington Disease – Discontinued Products 261

Huntington Disease – Product Development Milestones 262

Appendix 272

List of Tables

List of Tables

Number of Products under Development for Huntington Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Tables

Number of Products under Development for Huntington Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Huntington Disease – Pipeline by Addex Therapeutics Ltd, H1 2018

Huntington Disease – Pipeline by AFFiRiS AG, H1 2018

Huntington Disease – Pipeline by Annexon Inc, H1 2018

Huntington Disease – Pipeline by Azevan Pharmaceuticals Inc, H1 2018

Huntington Disease – Pipeline by BioCrea GmbH, H1 2018

Huntington Disease – Pipeline by BrainStorm Cell Therapeutics Inc, H1 2018

Huntington Disease – Pipeline by Celon Pharma SA, H1 2018

Huntington Disease – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Huntington Disease – Pipeline by Evotec AG, H1 2018

Huntington Disease – Pipeline by Exicure Inc, H1 2018

Huntington Disease – Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Huntington Disease – Pipeline by Genervon Biopharmaceuticals LLC, H1 2018

Huntington Disease – Pipeline by Horizon Pharma Plc, H1 2018

Huntington Disease – Pipeline by Immungenetics AG, H1 2018

Huntington Disease – Pipeline by InMed Pharmaceuticals Inc, H1 2018

Huntington Disease – Pipeline by Kadmon Corp LLC, H1 2018

Huntington Disease – Pipeline by Living Cell Technologies Ltd, H1 2018

Huntington Disease – Pipeline by Medesis Pharma SA, H1 2018

Huntington Disease – Pipeline by MindImmune Therapeutics Inc, H1 2018

Huntington Disease – Pipeline by Mitochon Pharmaceuticals Inc, H1 2018

Huntington Disease – Pipeline by Neurimmune Holding AG, H1 2018

Huntington Disease – Pipeline by Neurocrine Biosciences Inc, H1 2018

Huntington Disease – Pipeline by NeuroNascent Inc, H1 2018

Huntington Disease – Pipeline by New World Laboratories Inc, H1 2018

Huntington Disease – Pipeline by nLife Therapeutics SL, H1 2018

Huntington Disease – Pipeline by Novartis AG, H1 2018

Huntington Disease – Pipeline by Omeros Corp, H1 2018

Huntington Disease – Pipeline by Oryzon Genomics SA, H1 2018

Huntington Disease – Pipeline by Priavoid GmbH, H1 2018

Huntington Disease – Pipeline by Probiodrug AG, H1 2018

Huntington Disease – Pipeline by ProQR Therapeutics NV, H1 2018

Huntington Disease – Pipeline by PTC Therapeutics Inc, H1 2018

Huntington Disease – Pipeline by QR Pharma Inc, H1 2018

Huntington Disease – Pipeline by reMYND NV, H1 2018

Huntington Disease – Pipeline by Shire Plc, H1 2018

Huntington Disease – Pipeline by SOM Biotech SL, H1 2018

Huntington Disease – Pipeline by Spark Therapeutics Inc, H1 2018

Huntington Disease – Pipeline by Stealth BioTherapeutics Inc, H1 2018

Huntington Disease – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Huntington Disease – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018

Huntington Disease – Pipeline by Ultragenyx Pharmaceutical Inc, H1 2018

Huntington Disease – Pipeline by UniQure NV, H1 2018

Huntington Disease – Pipeline by Vaccinex Inc, H1 2018

Huntington Disease – Pipeline by Vertex Pharmaceuticals Inc, H1 2018

Huntington Disease – Pipeline by Vitality Biopharma Inc, H1 2018

Huntington Disease – Pipeline by Voyager Therapeutics Inc, H1 2018

Huntington Disease – Pipeline by Vybion Inc, H1 2018

Huntington Disease – Pipeline by WAVE Life Sciences Ltd, H1 2018

Huntington Disease – Dormant Projects, H1 2018

Huntington Disease – Dormant Projects, H1 2018 (Contd..1), H1 2018

Huntington Disease – Dormant Projects, H1 2018 (Contd..2), H1 2018

Huntington Disease – Dormant Projects, H1 2018 (Contd..3), H1 2018

Huntington Disease – Dormant Projects, H1 2018 (Contd..4), H1 2018

Huntington Disease – Dormant Projects, H1 2018 (Contd..5), H1 2018

Huntington Disease – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Huntington Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Figures

Number of Products under Development for Huntington Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports